DMC Group LLC Has $407,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

DMC Group LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.1% in the 4th quarter, Holdings Channel reports. The fund owned 5,231 shares of the medical device company’s stock after selling 651 shares during the quarter. DMC Group LLC’s holdings in DexCom were worth $407,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co lifted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the third quarter worth $57,000. Finally, Park Place Capital Corp raised its holdings in shares of DexCom by 3,516.7% during the fourth quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock worth $68,000 after acquiring an additional 844 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $86.43 on Thursday. The company has a market capitalization of $33.76 billion, a price-to-earnings ratio of 51.75, a PEG ratio of 2.23 and a beta of 1.12. The stock’s 50 day moving average is $80.00 and its 200-day moving average is $76.52. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Royal Bank of Canada lowered their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.